Curriculum · Public Health and Communicable Diseases
Host-directed therapy in tuberculosis
What it is
Host-directed therapy (HDT) is TB therapy that modifies specific aspects of the host-pathogen interaction and its downstream consequences. It pulls in two directions at once: augment pathogen killing, and reduce inflammation.
The goals of TB-HDTs are to improve outcomes for drug-resistant TB, to shorten treatment duration for all TB types, to improve preventative therapy, and to decrease host pathology, including for TB-IRIS and early mortality.
How it is treated
HDT is chosen against a step in Mtb pathogenesis. After phagocytosis the phagosome is permeabilized by ESX-1, and ManLAM inhibits phagolysosome fusion; on the other side sit the inflammatory pathways — cytokine production such as TNF, inflammasome activation, immune receptor expression, immune signalling pathways, ROS production, MMP production, and leukotriene and prostaglandin production. Each of these can be acted on.
- Promote phagolysosome fusion: metformin. Promote phagosome acidification and maturation: imatinib.
- Induce cathelicidin and other antimicrobial peptides: vitamin D and HDAC inhibitors.
- Induce autophagy: gefitinib, vitamin D and mTOR inhibitors.
- Inhibit inflammation: corticosteroids, TNF blockers, PDE4 inhibitors, leukotriene inhibitors, statins, PPAR agonists and COX inhibitors.
- Prevent lung damage: MMP inhibitors.
The drugs considered for repurposing as TB-HDTs follow the same logic. Statins have pleotropic effects and both decrease inflammation and improve killing. Phenylbutyrate with D3 acts as an HDAC inhibitor through cathelicidin to improve Mtb killing. Aspirin and ibuprofen work on arachidonic acid metabolism to decrease inflammation, and zileuton is a leukotriene synthesis inhibitor. Doxycycline is an MMP inhibitor and decreases tissue destruction. Sildenafil, CC-11050 and cilostazol are phosphodiesterase inhibitors and are anti-inflammatory, and so are the TZDs, whose pathway is PPARγ agonists. Anti-PD-1 and -LAG-3 are checkpoint inhibitors and act as immunomodulators, and bevacizumab, an anti-VEG-F antibody, increases drug to the granuloma.